Paradigm Biocapital Advisors LP
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Paradigm Biocapital Advisors LP reported 35 stock positions worth $4.9 billion. Its top holding was Arcellx (ACLX) at 13.5% of the portfolio, followed by Revolution Medicines (RVMD, 13.2%) and Nuvalent Class A (NUVL, 11.1%). Compared with Q4 2025, it opened 10 new positions, sold out of 4, added to 13 and reduced 7. The biggest buy was a new position in Insmed (INSM) and the biggest sale an exit from Cidara Therapeutics (CDTX).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001855655
- Portfolio Value
- $4.9B (Q1 2026)
- SEC Filing
- 0001855655-26-000011 ↗ filed May 15, 2026
Holdings Value
Holdings 35 stocks · $4.9B
| ACLX Arcellx Inc. | 13.55% | 5,774,016 | $663.0M | Add +0.9% |
| RVMD Revolution Medicines Inc. | 13.22% | 6,655,703 | $647.3M | Add +0.2% |
| NUVL Nuvalent Inc. Class A | 11.15% | 5,324,433 | $545.5M | Add +1.0% |
| PCVX Vaxcyte Inc. | 5.69% | 4,793,020 | $278.5M | Add +17.8% |
| EWTX Edgewise Therapeutics Inc. | 4.74% | 7,365,038 | $232.0M | Add +12.6% |
| GMAB Genmab A/S -SP ADR | 4.37% | 7,967,836 | $213.8M | Add +13.2% |
| INSM Insmed Inc. | 4.19% | 1,254,488 | $205.1M | New |
| TARS Tarsus Pharmaceuticals Inc. | 3.67% | 2,562,154 | $179.7M | No change |
| BLTE Belite Bio Inc. - ADR | 3.63% | 1,114,784 | $177.7M | New |
| ERAS Erasca Inc. | 3.44% | 10,392,702 | $168.2M | Reduce -26.6% |
| CNTA Centessa Pharmaceuticals Ltd. | 2.90% | 3,574,048 | $142.0M | New |
| OLMA Olema Pharmaceuticals Inc. | 2.44% | 8,020,576 | $119.6M | Add +6.3% |
| TERN Terns Pharmaceuticals Inc. | 2.39% | 2,216,499 | $116.9M | Add +173.6% |
| ORKA Oruka Therapeutics Inc. | 2.33% | 2,320,316 | $113.8M | Add +35.7% |
| APGE Apogee Therapeutics Inc. | 2.32% | 1,348,243 | $113.5M | Add +20.0% |
| SYRE Spyre Therapeutics Inc. | 2.02% | 1,957,266 | $98.7M | Add +33.4% |
| CYTK Cytokinetics Inc. | 1.99% | 1,480,857 | $97.6M | New |
| ABVX Abivax SA-ADR | 1.76% | 772,473 | $86.0M | Reduce -45.5% |
| TNGX Tango Therapeutics Inc. | 1.71% | 4,009,679 | $83.9M | New |
| MAZE Maze Therapeutics Inc. | 1.67% | 2,744,399 | $81.9M | New |
| TYRA Tyra Biosciences Inc. | 1.61% | 2,054,991 | $78.7M | New |
| VRDN Viridian Therapeutics Inc. | 1.26% | 3,148,893 | $61.6M | Add +118.2% |
| SRRK Scholar Rock Holding Corp. | 1.23% | 1,226,080 | $60.3M | Reduce -60.0% |
| MIRM Mirum Pharmaceuticals Inc. | 1.18% | 625,000 | $57.7M | New |
| EYPT Eyepoint Inc. | 0.83% | 3,142,437 | $40.5M | Reduce -14.9% |
| LXEO Lexeo Therapeutics Inc. | 0.73% | 6,184,134 | $35.5M | Add +29.8% |
| MANE Veradermics Inc. | 0.68% | 525,000 | $33.2M | New |
| VOR Vor Biopharma Inc. | 0.64% | 1,750,000 | $31.2M | No change |
| URGN Urogen Pharma Ltd. | 0.63% | 1,703,949 | $30.6M | Reduce -61.9% |
| GPCR Structure Therapeutics Inc. | 0.54% | 545,287 | $26.3M | New |
| IVA Inventiva SA - ADR | 0.45% | 4,000,000 | $22.2M | No change |
| ORIC Oric Pharmaceuticals Inc. | 0.44% | 1,701,217 | $21.6M | Reduce -29.1% |
| ASMB Assembly Biosciences Inc. | 0.38% | 665,251 | $18.5M | No change |
| BBOT Bridgebio Oncology Therapeut | 0.16% | 868,213 | $7.8M | Reduce -61.6% |
| KLRS Kalaris Therapeutics Inc. | 0.08% | 700,000 | $4.0M | No change |
Portfolio Sells Q4 2025 → Q1 2026
| CDTX Cidara Therapeutics Inc. | Sold out | 0.00% | −4.49 |
| ABVX Abivax SA-ADR | Reduce -45.5% | 1.76% | −3.36 |
| CRNX Crinetics Pharmaceuticals Inc. | Sold out | 0.00% | −2.76 |
| SRRK Scholar Rock Holding Corp. | Reduce -60.0% | 1.23% | −2.38 |
| URGN Urogen Pharma Ltd. | Reduce -61.9% | 0.63% | −2.18 |
| BBIO Bridgebio Pharma Inc. | Sold out | 0.00% | −1.40 |
| EYPT Eyepoint Inc. | Reduce -14.9% | 0.83% | −0.98 |
| OCUL Ocular Therapeutix Inc. | Sold out | 0.00% | −0.95 |
| BBOT Bridgebio Oncology Therapeut | Reduce -61.6% | 0.16% | −0.60 |
| ORIC Oric Pharmaceuticals Inc. | Reduce -29.1% | 0.44% | −0.09 |
| ERAS Erasca Inc. | Reduce -26.6% | 3.44% | +2.03 |
Portfolio Buys Q4 2025 → Q1 2026
| INSM Insmed Inc. | New | 4.19% | +4.19 |
| BLTE Belite Bio Inc. - ADR | New | 3.63% | +3.63 |
| ACLX Arcellx Inc. | Add +0.9% | 13.55% | +3.55 |
| CNTA Centessa Pharmaceuticals Ltd. | New | 2.90% | +2.90 |
| CYTK Cytokinetics Inc. | New | 1.99% | +1.99 |
| TNGX Tango Therapeutics Inc. | New | 1.71% | +1.71 |
| MAZE Maze Therapeutics Inc. | New | 1.67% | +1.67 |
| TYRA Tyra Biosciences Inc. | New | 1.61% | +1.61 |
| TERN Terns Pharmaceuticals Inc. | Add +173.6% | 2.39% | +1.51 |
| MIRM Mirum Pharmaceuticals Inc. | New | 1.18% | +1.18 |
| ORKA Oruka Therapeutics Inc. | Add +35.7% | 2.33% | +0.94 |
| SYRE Spyre Therapeutics Inc. | Add +33.4% | 2.02% | +0.73 |
| MANE Veradermics Inc. | New | 0.68% | +0.68 |
| PCVX Vaxcyte Inc. | Add +17.8% | 5.69% | +0.67 |
| GPCR Structure Therapeutics Inc. | New | 0.54% | +0.54 |
| EWTX Edgewise Therapeutics Inc. | Add +12.6% | 4.74% | +0.39 |
| VRDN Viridian Therapeutics Inc. | Add +118.2% | 1.26% | +0.06 |
| APGE Apogee Therapeutics Inc. | Add +20.0% | 2.32% | +0.05 |
| LXEO Lexeo Therapeutics Inc. | Add +29.8% | 0.73% | −0.54 |
| RVMD Revolution Medicines Inc. | Add +0.2% | 13.22% | −0.94 |
| GMAB Genmab A/S -SP ADR | Add +13.2% | 4.37% | −1.44 |
| OLMA Olema Pharmaceuticals Inc. | Add +6.3% | 2.44% | −2.61 |
| NUVL Nuvalent Inc. Class A | Add +1.0% | 11.15% | −3.05 |
Options Activity Q4 2025 → Q1 2026
| XBI SS SPDR S&P Biotech ETF | put | Sold out | 1,500,000 | $182.9Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 28 | $5.3B | RVMD, NUVL, EWTX, GMAB, SYRE |
| Q1 2026 | 35 | $4.9B | ACLX, RVMD, NUVL, PCVX, EWTX |
| Q4 2025 | 29 | $3.7B | NUVL, RVMD, ACLX, GMAB, TARS |
| Q3 2025 | 33 | $3.4B | NUVL, MRUS, ACLX, RVMD, TARS |
| Q2 2025 | 28 | $2.3B | NUVL, ACLX, MRUS, RVMD, TARS |
| Q1 2025 | 27 | $2.2B | NUVL, ACLX, RVMD, ONC, MRUS |
| Q4 2024 | 28 | $2.9B | NUVL, ACLX, ARGX, RVMD, JANX |
| Q3 2024 | 31 | $2.9B | NUVL, ACLX, ARGX, RVMD, CRNX |
| Q2 2024 | 35 | $2.6B | NUVL, ARGX, ACLX, RVMD, SRPT |
| Q1 2024 | 34 | $2.8B | NUVL, ACLX, ARGX, IRON, CRNX |